| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56874SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33200 | |||
| IHC-Prediluted | NBP2-48225 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-39113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2219SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NB110-87318AF405 | |||
| Alexa Fluor 488 | NB110-87318AF488 | |||
| Alexa Fluor 647 | NB110-87318AF647 | |||
| Alexa Fluor 700 | NB110-87318AF700 | |||
| Biotin | NB110-87318B | |||
| DyLight 488 | NB110-87318G | |||
| DyLight 550 | NB110-87318R | |||
| DyLight 650 | NB110-87318C | |||
| HRP | NB110-87318H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-87318SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56565SS | |||
| Azide and BSA Free | NBP2-33230 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Non-Recombinant Monoclonal | NB600-1159SS | |||
| Azide and BSA Free | NBP2-33250 | |||
| Non-Recombinant Monoclonal | NB600-1159 | |||
| BSA Free | NBP3-07012SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-582SS | |||
| Azide and BSA Free | NBP2-80959 | |||
![Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Immunohistochemistry analysis of sectioned tumor tissues from the MDA-MB-231 study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p<0.05 vs tumor volume of the control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-017-01230-4), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-NB100-56113-img0005.jpg "<b>Biological Strategies Validation. </b>Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Immunohistochemistry analysis of sectioned tumor tissues from the MDA-MB-231 study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p<0.05 vs tumor volume of the control. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-017-01230-4), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - The protein expression levels of Bcl-2, Bax and cleaved caspase-3 were detected in the different groups using Western blotting and were normalized to the housekeeping gene GAPDH. Image collected and cropped by CiteAb from the following publication (onlinelibrary.wiley.com/doi/abs/10.1111/jcmm.14135), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Western-Blot-NB100-56113-img0006.jpg)
![Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Cell apoptosis was detected by flow cytometric analysis, and the percentage of apoptotic cells transfected with miR-200c inhibitor or NC inhibitor and treated with AngII or PBS for 48 h was determined. Image collected and cropped by CiteAb from the following publication (onlinelibrary.wiley.com/doi/abs/10.1111/jcmm.14135), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Western-Blot-NB100-56113-img0007.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Dog ischemic brain stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved)( NB100-56113) at 1:2000. Staining is seen in the nuclei of dying neurons (black arrow) but not in the morphologically normal nuclei (open arrows). Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0003.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Irradiated mouse spleen stained for Active/Cleaved Caspase-3 expression using Caspase-3 Antibody - (active/cleaved) (NB100-56113) at 1:2000. Staining is seen in the nuclei of a subset of the cell population. Caspase-3 expression in the nucleus is considered to be a marker of active/caspase-3 expression and apoptosis. Hematoxylin-eosin counterstain.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-active-cleaved-Immunohistochemistry-Paraffin-NB100-56113-img0004.jpg)
![Immunohistochemistry: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Pathology in DOX treated acute & recovery phase mice. Regions of myofiber loss & frank replacement fibrosis were noted, most commonly in atria (A, acute phase), & rarely in ventricles (D, recovery phase). These areas were accompanied by macrophage infiltration (B, E) & myofibroblast proliferation (C) consistent with fibroplasia. Rare myofibers were matrix metalloproteinase 2 (F, recovery phase animal) or caspase-3 positive (G, acute phase animal). Reticulin staining (A, D); Immunohistochemistry: Iba 1(B, E; macrophages), alpha SMA (C), MMP-2 (F) & cleaved caspase -3 (G) Bar = 100µm (A-C); 50µm (D-F); 20µm (G). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31263061), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241530428.jpg)
![Western Blot: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Antidepressants-mediated effect on cellular protein content. HT-22 cells were treated with antidepressants for 48 & 96 h & densitometry analysis of NF-kappa B (b), p16 (c), p21 (d), p27 (e), p53 (f), TRF1 (g), TRF2 (h), calnexin (i), NuMa (j), cleaved caspase 3 (k), Bcl-2 (l) was evaluated. Representative Western Blots are presented (a). Bars indicate SD, n = 3, ***/^^^p < 0.001, **/^^p < 0.01, */^p < 0.05, no indication—no statistical significance (one-way ANOVA & Dunnett’s a posteriori test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31278507), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-310202415175224.jpg)
![Immunocytochemistry/ Immunofluorescence: Caspase-3 Antibody - (active/cleaved) [NB100-56113] - Morphological changes & expression of key apoptosis-related molecules in 4T1 cells after DE-EDCP treatment(A) Morphological changes of 4T1 cells exposed to various concentrations of DE-EDCP for 24h. (B) Immunofluorescence staining for Bcl-2 (green), Bax (green) & cleaved caspase-3 (green) together with DNA staining with DAPI (blue) in 4T1 cells incubated with DE-EDCP or cisplatin (31.25 μM) for 24h, as well as in untreated cells (magnification at x200). (C) mRNA expression of Bcl-2, Bax & caspase-3 quantified by RT-PCR in 4T1 cells after DE-EDCP 24h treatment. DE-EDCP treatment markedly increased the expression of Bax & caspase-3 mRNA & decreased the expression of Bcl-2 mRNA in 4T1 cells. beta -actin mRNA was used as an internal control. Data points are represented by the expression ratio & mean±SD fold of control in 4T1 cells. (* Bcl-2-: DE-EDCP vs. untreated p=0.03; DE-EDCP vs. cisplatin p=0.006; cislatin vs. untreated p=0.001; Bax-: DE-EDCP vs. untreated p=0.011; cislatin vs. untreated p=0.009; caspase-3-: DE-EDCP vs. untreated p=0.015; DE-EDCP vs. cisplatin p=0.021) Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56113_rabbit-polyclonal-caspase-3-antibody-active-cleaved-31020241682116.jpg)
![Simple Western: beta-Actin Antibody [NB100-56874] - Image shows a specific band for Beta Actin in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Simple-Western-NB100-56874-img0007.jpg "Simple Western: beta-Actin Antibody [NB100-56874] - Image shows a specific band for Beta Actin in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: beta-Actin Antibody [NB100-56874] - Specific bands are seen in various cell lysates at the same molecular weight. A: human brain, B: mouse brain, C: rat brain, D: human lung, and E: human spleen tissue probed using beta actin antibody at 0.25 ug/mL.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: beta-Actin Antibody [NB100-56874] - Actin was detected in NIH-3T3 cells fixed with methanol using rabbit anti-mouse Actin antibody (NB100-56874) at 1:100 dilution, overnight at 4C. Cells were stained using Northern Lights 557 conjugated anti-rabbit IgG secondary antibodies (NL004) and counterstained with DAPI.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56874-img0009.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Analysis of NS5B protein expression after transfecting NS5B and La autoantigen siRNAs: HCV-infected Huh-7. 5 cells were treated with siRNAs against La autoantigen and NS5B as mentioned above. After 48h total cellular protein was isolated and subjected to western blot analysis. The analysis indicates downregulation of La autoantigen (upper gel) and NS5B (middle gel) andI2-actin (lower gel). Image collected and cropped by Citeab from the following publication (Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication. Hepat Res Treat (2016)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0010.jpg)
![Immunohistochemistry-Paraffin: beta-Actin Antibody [NB100-56874] - Analysis of human spleen using antibody at 10 ug/mL.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Immunohistochemistry-Paraffin-NB100-56874-img0005.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Decreasing amounts of human ovary tissue lysate were probed using beta actin antibody at 0.25 ug/mL: A) 40 ug, B) 30 ug, C) 20 ug, D) 10 ug per lane.](http://images.novusbio.com/fullsize/beta-Actin-Antibody-Western-Blot-NB100-56874-img0003.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Simultaneous downregulation of multiple genes more effectively inhibits HCV replication: Huh-7.5 cells in a similar experimental setup as mentioned in Figure 1 were transfected with following combinations of siRNAs: La autoantigen + NS5B, La autoantigen + hVAP-A, La autoantigen + PSMA7, NS5B + hVAP-A, NS5B + PSMA7, & PSMA7 + hVAP-A. Downregulation of viral replication were determined by RT-PCR as shown in (a). (b) represents densitometry analysis of HCV NS5B downregulation. The data represent mean ± standard deviation. ∗P value < 0.05 versus control was considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415304250.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415532081.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-31020241612664.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202415525271.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-310202416579.jpg)
![Western Blot: beta-Actin Antibody [NB100-56874] - Downregulation of La autoantigen, hVAP-A, PSMA7, & NS5B leads to reduction in viral replication: overnight grown Huh-7.5 cells were transfected with La autoantigen, hVAP-A, & PSMA7 siRNAs for 48 h. Cells were then infected with the virus & again transfected with same siRNAs. After incubation total RNA was isolated & subjected to RT-PCR. NS5B siRNA was transfected once only after cells were infected. (a), (c), (e), & (g) represent RT-PCR results for target genes & NS5B gene upon treatment with La autoantigen, hVAP-A, PSMA7, & NS5B siRNAs, respectively. Densitometric analysis of (a), (c), (e), & (g) images is expressed in percentage in (b), (d), (f), & (h), respectively. The data represent mean ± standard deviation. ∗P value < 0.05 versus control considered statistically significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27446609), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56874_rabbit-polyclonal-beta-actin-antibody-31020241554545.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647. Image from the AF647 version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-17720249362612.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin [AE1 + AE3] Antibody NBP2-33200AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488. Image from the AF488 version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-17720241003217.jpg)
![Flow Cytometry: Cytokeratin, pan Antibody (AE-1/AE-3) [NBP2-29429] - An intracellular stain was performed on HeLa cells with pan Cytokeratin Antibody (AE1 + AE3) NBP2-33200PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image from the PE version of this antibody.](http://images.novusbio.com/fullsize/nbp2-29429_mouse-monoclonal-cytokeratin-pan-antibody-ae-1-ae-3-imgenex-nbo-135a-20ug-1772024944230.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - PrP-mediated increase in IC iron downregulates glucose transporters in the brain, neuroretina, and the liver: A similar evaluation of retinal lysates shows upregulation of Glut1 in PrP-/- relative to Tg40 PrP samples (lanes 1 & 3). Iron overloading downregulates Glut1 in Tg40 PrP samples relative to untreated controls, but has minimal effect on similarly treated PrP-/- samples (lanes 2 & 4). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24786-1) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: Glut1 Antibody [NB110-39113] - PrP-mediated increase in IC iron downregulates glucose transporters in the brain, neuroretina, and the liver: A similar evaluation of retinal lysates shows upregulation of Glut1 in PrP-/- relative to Tg40 PrP samples (lanes 1 & 3). Iron overloading downregulates Glut1 in Tg40 PrP samples relative to untreated controls, but has minimal effect on similarly treated PrP-/- samples (lanes 2 & 4). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24786-1) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: Glut1 Antibody [NB110-39113] - Western blot of GLUT1 on mouse kidney membrane protein (lane A) and rat kidney membrane protein (lane B).](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0006.jpg)
![Immunohistochemistry-Paraffin: Glut1 Antibody [NB110-39113] - Immunohistochemical analysis of FFPE tissue section of human placenta using 1:200 dilution of Glut1 antibody. The staining was developed using HRP-DAB detection method and the sections were further counterstained with hematoxylin. This antibody generated a specific strong membrane cytoplasmic staining of Glut1 primarily in the syncytiotrophoblast layers of various villi and in the red blood cells (RBCs). Cytotrophoblasts showed a very weak expression of this protein.](http://images.novusbio.com/fullsize/Glut1-Antibody-Immunohistochemistry-Paraffin-NB110-39113-img0011.jpg)
![Flow Cytometry: Glut1 Antibody [NB110-39113] - An intracellular stain was performed on HepG2 with NB110-39113 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/Glut1-Antibody-Flow-Cytometry-NB110-39113-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: Glut1 Antibody [NB110-39113] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-GLUT1 at a 1:200 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective](http://images.novusbio.com/fullsize/Glut1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-39113-img0013.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - Analysis of HeLa lysates using NB110-39113. Image courtesy of Gregg Semenza (PMID: 21620138).](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0007.jpg)
![Western Blot: Glut1 Antibody [NB110-39113] - Glut1 in human brain lysate (55 kDa). Antibody at 1:500. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Glut1-Antibody-Western-Blot-NB110-39113-img0016.jpg)
![<b>Biological Strategies Validation. </b>Flow Cytometry: Glut1 Antibody [NB110-39113] - Flow cytometry analysis using the PE conjugate of NB110-39113. Staining of Glut 1 expression on CD4+ T cells stimulated with anti-CD3/CD28 beads and insulin (1ug/mL) for 5 days in culture media with additional glucose provided. FMO control (red) and isotype control (blue, NBP2-24983) were compared to CD4+ T cells (orange), and this PE conjugated Glut 1 antibody positively stained CD4+ lymphocytes isolated from Mouse. Flow cytometry image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Glut1-Antibody-Flow-Cytometry-NB110-39113-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: Glut1 Antibody - BSA Free [NB110-39113] - LAIR-1 inhibits Glut1-related glucose uptake in OS cells. a Heatmap showing the levels of differentially expressed mRNAs. b Top 20 KEGG pathway annotation categories for target gene functions of predicted mRNAs. c Selected significantly differentially expressed mRNA-related to EMT in RNA-seq data between two groups, ***P < 0.001. d qPCR validation of differentially expressed EMT-related genes in LV-NC & LV-LAIR-1-overexpressing OS cells, **P < 0.01. e Glut1 expression analyzed by western blotting. f Immunofluorescence staining of Glut1 in the LV-LAIR-1-overexpressing OS cells. Scale bar = 50 μm. Data were obtained from at least two independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32563267), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202415175286.jpg)
![Western Blot: Glut1 Antibody - BSA Free [NB110-39113] - LAIR-1 inhibits Glut1-related glucose uptake in OS cells. a Heatmap showing the levels of differentially expressed mRNAs. b Top 20 KEGG pathway annotation categories for target gene functions of predicted mRNAs. c Selected significantly differentially expressed mRNA-related to EMT in RNA-seq data between two groups, ***P < 0.001. d qPCR validation of differentially expressed EMT-related genes in LV-NC & LV-LAIR-1-overexpressing OS cells, **P < 0.01. e Glut1 expression analyzed by western blotting. f Immunofluorescence staining of Glut1 in the LV-LAIR-1-overexpressing OS cells. Scale bar = 50 μm. Data were obtained from at least two independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32563267), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202415334922.jpg)
![Simple Western: Glut1 Antibody - BSA Free [NB110-39113] - Protein changes in ONHAs corroborate bioenergetics data. (A) Glucose transporter-1 protein levels in Stretched ONH astrocytes are significantly higher than Control (*p = 0.0225, n = 7 Control, n = 8 Stretch). Retinal lysate from a 2 month-old mouse was used as a positive control for each protein analyzed, while negative control was the signal obtained when no primary antibody was included in the capillary. (B) Lactate dehydrogenase-A, the astrocyte-specific isoform of the enzyme that catalyzes the interconversion of pyruvate & lactate, has equivalent protein levels in Control & Stretch ONH astrocytes. (C) Glucose-6-phosphate dehydrogenase, the enzyme that shunts glucose into the pentose phosphate pathway, is no different in Control & Stretch ONH astrocytes. (D) Glutamine synthetase, the enzyme that synthesizes glutamine from glutamate, is no different in Control & Stretch ONH astrocytes. (E) The monomeric form of glutamate-aspartate transporter (GLAST) has significantly higher protein levels in the Stretch as compared to the Control ONH astrocytes (p = 0.020; n = 4 Control, n = 5 Stretch). (F) GLAST dimer protein levels are no different in Control & Stretch ONH astrocytes. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35992925), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-39113_rabbit-polyclonal-glut1-antibody-310202416284917.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0015.jpg "Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - IHC and Immunofluorescence of wounded tissue and normal unwounded skin. Representative images for immunofluorescent staining of PHD-2 on healed wounded skin and adjacent normal unwounded skin of wild type, heterozygous K14-Cre/homozygous floxed PHD-2, and heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice at 400x magnification. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - In vitro analysis of PHD-2 knockout and protein quantification.Western blot data for PHD-2 knockout in fibroblasts of heterozygous Col1 alpha2-Cre-ER/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). D') Western blot data for PHD-2 knockout in keratinocytes of heterozygous K14-Cre/homozygous floxed PHD-2 mice compared to wild type mice (*p<0.05). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0093373), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Knockdown-Validated-NB100-2219-img0016.jpg)
![Immunohistochemistry-Paraffin: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of an FFPE mouse lung section using 1:200 dilution of EGLN1/PHD2 antibody. The staining was developed using HRP conjugated anti-rabbit secondary antibody and DAB reagent. The antibody generated a specific staining in the cytoplasm and nuclei of alveolar as well as bronchiolar epithelial cells. Cytoplasmic staining was observed in almost all cells while the nuclear positivity was seen in a subset of cells only.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-Paraffin-NB100-2219-img0014.jpg)
![Western Blot: EGLN1/PHD2 Antibody [NB100-2219] - Detection of EGLN1/PHD2 in mouse kidney lysate. ECL exposure, 20 seconds.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Western-Blot-NB100-2219-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - EGLN1/PHD2 antibody at 1:500 in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: EGLN1/PHD2 Antibody [NB100-2219] - Analysis of EGLN1/PHD2 in ARPE-19 cells using anti-PHD2 antibody. ICC/IF image submitted by a veriifed customer review.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2219-img0009.jpg)
![Immunohistochemistry: EGLN1/PHD2 Antibody [NB100-2219] - Staining of renal tubular epithelium in mouse using NB100-2219 at 2.5 ug/mL.](http://images.novusbio.com/fullsize/EGLN1-PHD2-Antibody-Immunohistochemistry-NB100-2219-img0010.jpg)
![Simple Western: Beclin 1 Antibody [NB110-87318] - Lane view shows a specific band for Beclin in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Simple-Western-NB110-87318-img0019.jpg "Simple Western: Beclin 1 Antibody [NB110-87318] - Lane view shows a specific band for Beclin in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: Beclin 1 Antibody [NB110-87318] - Total protein from human HeLa and mouse Neuro2A cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Beclin-1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Western-Blot-NB110-87318-img0012.jpg)
![Immunohistochemistry-Paraffin: Beclin 1 Antibody [NB110-87318] - Analysis of a FFPE tissue section of human breast cancer using Beclin 1 antibody (Lot 71917) at 1:300 dilution. The primary antibody bound to Beclin 1 antigen in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. Cytoplasmic staining can be seen in the cancer as well as the stromal cells. The signal was strongest in a subset of stromal cells which appears to be the cancer associated fibroblasts.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunohistochemistry-Paraffin-NB110-87318-img0017.jpg)
![Western Blot: Beclin 1 Antibody [NB110-87318] - Basal levels of autophagy in the hypothalamus of BACHD mice. The expression levels of selected autophagy markers were analyzed by Western blot in hypothalamic tissue from BACHD mice at 2, 6 and 12 months of age and compared with gender- and age-matched controls (n=3-6/group). The data showed a substantial maintenance of the autophagy flux, despite the presence of a metabolic phenotype in the BACHD mice already at early time points. The data in the graphs are expressed as mean +/- SEM, relative to the 2 months wt controls. The Western blots are representative of one sample for each group. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0083050), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Western-Blot-NB110-87318-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: Beclin 1 Antibody [NB110-87318] - Beclin 1/ATG6 Antibody [NB110-87318] - Beclin1 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-87318-img0020.jpg)
![Immunohistochemistry-Paraffin: Beclin 1 Antibody [NB110-87318] - Analysis of a FFPE tissue section of human breast cancer using Beclin 1 antibody (Lot F4) at 1:300 dilution. The primary antibody bound to Beclin 1 antigen in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. Cytoplasmic staining can be seen in the cancer as well as the stromal cells. The signal was strongest in a subset of stromal cells which appears to be the cancer associated fibroblasts.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunohistochemistry-Paraffin-NB110-87318-img0016.jpg)
![Western Blot: Beclin 1 Antibody [NB110-87318] - Image from verified customer review.](http://images.novusbio.com/fullsize/Beclin-1-ATG6-Antibody-Western-Blot-NB110-87318-img0010.jpg)
![Immunohistochemistry: Beclin 1/ATG6 Antibody [NB110-87318] - Staining of normal breast tissue.](http://images.novusbio.com/fullsize/Beclin-1-ATG6-Antibody-Immunohistochemistry-NB110-87318-img0006.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB110-87318] - Maintenance of basal levels of autophagy in mice overexpressing htt fragments in the hypothalamus.The expression levels of selected autophagy markers were analyzed by Western blot in mice bilaterally injected with rAAV5-htt853-18Q or rAAV5-htt853-79Q & compared to uninjected controls 8 weeks post injection (n = 6–7/group). The data displayed maintenance of the autophagy flux, despite the presence of a clear metabolic phenotype in the injected mice. The data in the graphs are expressed as mean ± SEM relative to the uninjected controls. The Western blots are representative of one sample for each group. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0083050), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-87318_rabbit-polyclonal-beclin-1-antibody-31020241539256.jpg)
![Western Blot: alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of Mouse Duodenum lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Western-Blot-NB300-978-img0007.jpg "Western Blot: alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of Mouse Duodenum lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: alpha-Smooth Muscle Actin Antibody [NB300-978] - SMA antibody staining on mouse fibroblasts. Primary antibody at 1:1000, incubation at 4C overnight. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Immunocytochemistry-Immunofluorescence-NB300-978-img0006.jpg)
![Immunohistochemistry-Frozen: alpha-Smooth Muscle Actin Antibody [NB300-978] - Infarcted mouse heart frozen tissue section immunostained with alpha-Smooth Muscle Actin Antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-Immunohistochemistry-Frozen-NB300-978-img0003.jpg)
![alpha-Smooth Muscle Actin Antibody [NB300-978] - (1ug/ml) staining of HeLa (A) and (2ug/ml) NIH3T3 (B) cell lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.](http://images.novusbio.com/fullsize/alpha-Smooth-Muscle-Actin-Antibody-NB300-978-img0008.jpg)
![Immunohistochemistry-Paraffin: Goat Polyclonal alpha-Smooth Muscle Actin Antibody [NB300-978] - Analysis of alpha-Smooth Muscle Actin Antibody on mouse heart tissue. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb300-978_goat-polyclonal-alpha-smooth-muscle-actin-antibody-immunohistochemistry-paraffin-61202594652..jpg)
![<b>Biological Strategies Validation. </b>P. gingivalis and its OMVs differentially induce inflammasome signaling and pyroptosis in murine macrophages. BMM were infected as before (2 h at MOI of 25:1, see Materials and Methods) with viable P. gingivalis (Pg), heat-killed-Pg (HK-Pg), OMVs, or heat-inactivated-OMVs (HI-OMVs) and the activation of inflammasome components in the lysates [or supernatants (sup) where indicated] measured after 24 h by Western blot; beta-actin serves as a loading control throughout. Western blot data are representative of at least three independent experiments. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fcimb.2017.00351/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-1-Antibody-14F468-Western-Blot-NB100-56565-img0015.jpg)
![Detection of Caspase-1 protein in a section of normal human colon using 5 ug/ml concentration of Caspase 1 antibody (clone 14F468). Distinct cytoplasmic staining along with some nuclear positivity was observed in crypts/mucosa, and staining was found to be more intense in the absorptive columnar epithelial cells. [10X Magnification]](http://images.novusbio.com/fullsize/Caspase-1-Antibody-14F468-Immunohistochemistry-Paraffin-NB100-56565-img0009.jpg)
![Normal lung from human using 5 ug/ml concentration of Caspase 1 antibody (clone 14F468). In this representative lung section, different type of cells including pseudostratified columnar epithelium of bronchiole and the simple squamous epithelium of alveoli may be seen to develop immunoreactivity for Caspase 1. [10X Magnification]](http://images.novusbio.com/fullsize/Caspase-1-Antibody-14F468-Immunohistochemistry-Paraffin-NB100-56565-img0010.jpg)
![Normal skin from human using 5 ug/ml concentration of Caspase 1 antibody (clone 14F468). Strong cytoplasmic/nuclear staining developed in all the epidermal cells, blood vessels and some cells of the dermal connective tissues layer. [10X Magnification]](http://images.novusbio.com/fullsize/Caspase-1-Antibody-14F468-Immunohistochemistry-Paraffin-NB100-56565-img0011.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Glucose fluctuations promoted the activation of NLRP3 inflammasome. (A) Immunofluorescence staining of NLRP3-ASC interaction in rat hearts. The heart sections were labeled with anti-NLRP3 (red), anti-ASC (green), & DAPI (blue) (n = 3 per group). (B–D) The mRNA levels of NLRP3, IL-1 beta & IL-18 in rat hearts of the three groups (n = 4 per group). (E–H) The protein expressions of NLRP3, ASC & cleaved caspase-1 in rat hearts of the three groups (n = 4 per group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35592403), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415175246.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Caspase-1 expression increases with age in human fibroblasts: a Immunoblot analysis of caspase-1 & ASC in human fibroblasts obtained from a donor at the ages of 49, 52 & 64 y/o. b Immunocytochemistry image of human fibroblasts stained for caspase-1 (green) & Phalloidin (red) from a donor at three different ages (49, 52 & 64 y/o). Bar graph: 100 μm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30473634), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415345329.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Aging alters expression of NLRP1 inflammasome components. Representative immunoblots & densitometric analysis of immunoblots for caspase-1 (Casp1), caspase-11 (Casp11), NLRP1, ASC, cleaved XIAP, P2X7 receptor (P2X7R) & pannexin-1 (PanX1) in brain lysates of young (Y) & aged (A) animals. Protein levels of cleaved caspase-1 & -11 are higher in aged animals compared to young. Protein levels of NLRP1 & ASC did not change with age whereas P2X7 receptor, the pannexin-1 protein & the cleaved fragment of XIAP are higher in aged animals than in young animals. beta -Tubulin was used as an internal standard & control for protein loading. Data are presented as mean +/- SEM. *p < 0.05, **p < 0.01, ***p < 0.005 compared with young. n = 6 per group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22133203), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415384197.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Role of NF-kappa B in glucose fluctuation-induced inflammasome-related myocardial fibrosis. (A) Immunofluorescence staining of NF-kappa B/p65 nucleation (n = 3 per group). (B,C) The phosphorylation level of NF-kappa B/p65 in rat hearts of the three groups (n = 4 per group). (D) Immunofluorescence staining of intracellular NLRP3–ASC interaction in the GF & GF + TPCA-1 groups. The NRCFs were labeled with anti-NLRP3 (red), anti-ASC (green), & DAPI (blue) (n = 3 per group). (E–G) After application of TPCA-1 (0.5 μM), the protein expressions of cleaved caspase-1 & collagen I were measured by western blot (n = 3 per group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35592403), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-31020241539719.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Inflammasome proteins are elevated in the cytosolic fraction of aged mice: a Representative image of immunoblot analyses of inflammasome proteins in the cytosolic fraction of the cortex of young (Y) & aged (A) mice. Quantification of immunoblot analysis of NLRC4 (b), caspase-1 (c), ASC (d), IL-18 (e) in the cortex. a Representative image of immunoblot analyses of inflammasome proteins in the cytosolic fraction of the hippocampus of young (Y) & aged (A) mice. Quantification of immunoblot analysis of NLRC4 (g), caspase-1 (h), caspase-11 (i), ASC (j), IL-1 beta (k) in the hippocampus. Data presented as mean+/-SEM. N = 5 per group. *p < 0.05 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30473634), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415392595.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - NLRP3 inhibition with MCC950 reversed myocardial fibrosis induced by glucose fluctuations. (A) Representative images of hematoxylin & eosin (HE) staining for myocardial tissue in the FBG + NaCl & FBG + MCC950 groups (n = 3 per group). (B–C) Representative images of myocardial fibrosis & fibrosis area (%) in the FBG + NaCl & FBG + MCC950 groups (n = 4 per group). (D–K) The protein expressions of NLRP3, cleaved caspase-1, TGF-beta 1, collagen I & collagen III in the FBG + NaCl & FBG + MCC950 groups (n = 6 per group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35592403), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415175211.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Inflammasome proteins are elevated in the cytosolic fraction of aged mice: a Representative image of immunoblot analyses of inflammasome proteins in the cytosolic fraction of the cortex of young (Y) & aged (A) mice. Quantification of immunoblot analysis of NLRC4 (b), caspase-1 (c), ASC (d), IL-18 (e) in the cortex. a Representative image of immunoblot analyses of inflammasome proteins in the cytosolic fraction of the hippocampus of young (Y) & aged (A) mice. Quantification of immunoblot analysis of NLRC4 (g), caspase-1 (h), caspase-11 (i), ASC (j), IL-1 beta (k) in the hippocampus. Data presented as mean+/-SEM. N = 5 per group. *p < 0.05 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30473634), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415395949.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Role of inflammasome in glucose fluctuation-induced myocardial fibrosis. (A) Immunofluorescence staining of intracellular NLRP3–ASC interaction examined by confocal microscopy. The NRCFs were labeled with anti-NLRP3 (red), anti-ASC (green), & DAPI (blue) (n = 3 per group). (B–G) After siRNA targeting NLRP3 transfection, the protein expressions of NLRP3, cleaved caspase-1 & collagen I were measured by western blot (n = 3 per group). (H) Representative images of immunofluorescence staining of intracellular alpha -SMA in the NG, HG, GF, & GF + siRNA groups (n = 3 per group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35592403), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-31020241534326.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Epirubicin suppresses the NLRP3 inflammasome in presence of autophagy inhibitors. (A) LPS/ATP-induced IL-1 beta secretion from PM in the absence or presence of bafilomycin & 3-MA is shown. Means ± SEM from 10 (IL-1 beta ) independent experiments are shown. (B) Representative immunoblot of LC3b after epirubicin & LPS/ATP treatments. (C,D) Representative immunoblots of inflammasome & autophagy components after inhibition with (C) bafilomycin or (D) 3-MA in PM whole cell lysates. Cells were treated with indicated concentrations of epirubicin treatment over 24 h, followed by LPS (10 ng/mL) in the absence or presence of bafilomycin (300 nM) or 3-MA (10 mM) for 3 h & NLRP3 activation by ATP (1 mM, 1 h). Whole cell lysates were subjected to SDS-PAGE (10% gel) & processed for immunoblot analysis with specific antibodies. Here, beta -actin served as loading control. Statistical tests: one-sample t-test (A) ** p < 0.01, *** p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31905600), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-31020241612614.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Genetic or pharmacologic disruption of Caspase 1 blocks LukAB-induced cytokine secretion but not cell death.(A) THP1 cells were transfected with siRNA against Caspase 1, ASC or a non-targeting sequence. Cell lysates were collected & analyzed by immunoblot to confirm knockdown of pro-Caspase 1 & ASC. (B) THP1 siRNA cells were incubated with propidium iodide & intoxicated with 50 ng/mL LukAB for 1 hour then analyzed by flow cytometry. (C & D) THP1 siRNA cells were either primed with LTA (500ng/mL) (C) or untreated (D) then intoxicated with LukAB (50ng/mL) for 1 hr before culture supernatants were analyzed for release of IL-1 beta (C) or IL-18 (D). (E & F) Primary CD14+ human monocytes were incubated with the indicated concentration of z-YVAD-FMK or VX-765 for 30 minutes. Primary monocytes were incubated in the presence of propidium iodide (E) then intoxicated with LukAB (50ng/mL) & analyzed by flow cytometry. (F) Primary monocytes were intoxicated with LukAB (50ng/mL) & culture supernatants were analyzed for release of IL-18. Propidium iodide staining & IL-18 secretion are reported as a fraction of measurement in primary cells not treated with inhibitor. Bars represent the mean ± standard error of the mean for at least two independent experiments, each performed in triplicate. Asterisks indicate significance at a p-value of ≤ 0.05 by Tukey’s multiple comparisons post-test for 1-way or 2-way ANOVA, as appropriate. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1004970), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415541952.jpg)
![Western Blot: Caspase-1 Antibody (14F468) - BSA Free [NB100-56565] - Probenecid reduces protein expression of NLRP1 inflammasome & ameliorates spatial learning deficits in aged rats. (A) Representative immunoblots of cleaved caspase-1, pannexin1 & P2X7R in hippocampal lysates of vehicle (Veh)-treated & probenecid (Pr)-treated 18-month-old rats. beta -tubulin was used as an internal control. (B) Densitometric analysis of immunoblots from brain lysates of cleaved caspase-1 (Casp1), P2X7 receptor (P2X7R), & pannexin1 (PanX1). (C-D) Aged animals underwent behavioral testing following either probenecid or vehicle treatment. (C) In a hippocampal-dependent spatial learning task via Morris water maze, latency to platform was measured on days 1-3 & 8-10. Probenecid-treatment improved latency to platform measured on the final day of testing (D) Mean path length was determined on day 10 of testing & probenecid-treated rats demonstrated significantly shorter mean path lengths than vehicle-treated controls. Drug treatment was administered twice daily for 3 days (days 7-9). Data are presented as mean +/- SEM *p < 0.05, **p < 0.005 compared to vehicle. N = 6-8/per group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22133203), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56565_mouse-monoclonal-caspase-1-antibody-14f468-310202415541990.jpg)
![Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Western-Blot-NBP3-07012-img0003.jpg "Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - ICC/IF analysis using the azide-free version of NB600-1159 at 1:10. HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40X.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0004.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) [NBP3-07012] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1R] NBP3-07012 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Flow-Cytometry-NBP3-07012-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Noxa Antibody (114C307.1R) NBP3-07012 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0001.jpg)
![Immunohistochemistry-Paraffin: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Immunohistochemical analysis of bouin-fixed, paraffin-embedded chronic lymphocytic leukemia (CLL) xenograft stained with Noxa antibody (1:2000), peroxidase-conjugate and DAB chromogen. Staining for 2 hr at RT was used.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024104467.jpg)
![Western Blot: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Detection by Western blot in RL-7 cells (a follicular lymphoma).](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959411.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on MCF7 cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959421.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on HeLa cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-17720249362613.jpg)
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0004.jpg "Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Hepatic SREBP1c and SREBP2 protein abundance in C57BL/6 mice assigned to a high-fat (HF) or a high-fat/exercise (HF + EX) group for 8 weeks. Cytosolic and nuclear SREBP1c abundance. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/jl/2013/908048/), licensed under a CC-BY license.")
![Western Blot: SREBP1 Antibody (2A4) [NB600-582] - Analysis of whole cell lysate from HeLa cells showing a single specific band for the expression of SREBP1 precursor protein (~120 kDa).](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Western-Blot-NB600-582-img0002.jpg)
![Simple Western: SREBP1 Antibody (2A4) [NB600-582] - Lane view shows a specific band for SREBP1 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Simple-Western-NB600-582-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: SREBP1 Antibody (2A4) [NB600-582] - KO and OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, and WT Bel-7402 cells. Data were expressed as mean -/+ standard error of the mean. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. WT group, respectively.](http://images.novusbio.com/fullsize/SREBP1-Antibody-2A4-Knockout-Validated-NB600-582-img0005.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the expression of Nrf2‐related signalling proteins in OA (660 μmol/L) & PA (330 μmol/L)‐induced HepG2 cells. GEN was added into HepG2 cells prior 1 h to stimulation of OA & PA for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm was detected by Western blot. (D & E) Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta & AMPK beta was detected by Western blot. F‐H, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control Group; *P < .05 & **P < .01 vs OA & PA Group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241534375.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - KO & OE of SREBP1 influenced lipid metabolism in Bel-7402 cells. (A) Total cellular TG content of SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (B) HPLC-MS determination of the SFAs to MUFAs ratios (palmitic acid to palmitoleic acid, 16:0 to 16:1) (stearic acid to oleic acid, 18:0 to 18:1) as well as the content of 16:0, 16:1, 18:0, & 18:1 in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (C) The transcript level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. (D & E) The protein level of lipid-associated genes in SREBP1-KO, SREBP1-OE, & WT Bel-7402 cells. Data were expressed as mean ± standard error of the mean. *P < 0.05, **P < 0.01, & ***P < 0.001 vs. WT group, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202415384185.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Construction of knockout (KO) & overexpression (OE) cell lines. (A) The sequencing results of KO positive clone cells; (B) The messenger RNA (mRNA) level of SREBP1 in wild type (WT) & OE Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group; (C & D) The protein level of SREBP1 in WT, OE, & KO Bel-7402 cells. Data were expressed as mean ± standard error of the mean. ***P < 0.001 vs. WT group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31297058), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-31020241539748.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416161836.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - p75NTR stimulation activated SREBP1 & SREBP2 in Huh7 hepatocyte cells.Human Huh7 cells were stimulated with 10 ng/ml pro-NGF or 50 ng/ml NGF for 16 h followed by immunoblotting using antibodies to detect the presence of cleaved/activated SREBP1 & SREBP2. a SREBP1, immunoblots & b quantification. Values are mean ± SD, n = 3. **P < 0.01 & *p < 0.05 for treated vs. control cells. c, d SREBP2. Cells were treated with 10 ng/ml pro-NGF in the absence or presence of 0.5 μM PF429242 (PF), which is a selective inhibitor of the Site 1 protease (S1P). c Immunoblots & d quantification. PF decreased the amount of processed SREBP2 in these cells; however, addition of pro-NGF increased the relative level of cleaved SREBP2. Values are mean ± SD, n = 3. *p < 0.05 for treated vs. the corresponding control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31296846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416175210.jpg)
![Western Blot: SREBP1 Antibody (2A4) - BSA Free [NB600-582] - Effect of GEN on the protein expression of Nrf2, ACC & mTORC signalling pathways in tyloxapol‐induced mice. GEN (50, 75, 100 mg/kg) was administered to WT or Nrf2−/− mice prior 1 h to stimulation of tyloxapol (500 mg/kg) for 18 h. A‐C, Protein expression of Nrf2, PPAR alpha , PPAR gamma in nucleus & HO‐1 in cytoplasm of WT mice was detected by Western blot. (D & E) Protein expression of Nrf2, PPAR alpha & PPAR gamma in Nrf2−/− mice was detected by Western blot. F‐H, Protein expression of P‐ACC, ACC, P‐AKT, AKT, P‐AMPK alpha , AMPK alpha , P‐AMPK beta , AMPK beta in WT & Nrf2−/− mice was detected by Western blot. I‐M, Protein expression of PI3K, P‐mTORC, mTORC, P‐S6K, S6K, P‐S6, S6, SREBP‐1c & HMGB1 WT & Nrf2−/− mice was detected by Western blot. The similar results were collected from three dependent experiments. All data were expressed by mean ± SEM (n = 5 in each group). ##P < .01 vs Control group; *P < .05 & **P < .01 vs Tyloxapol group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32293113), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-582_mouse-monoclonal-srebp1-antibody-2a4-310202416171460.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Staining of Human Liver (A) and Tonsil (B) with antibody at 0.001 ug/mL and Rat Brain lysate (C) with antibody at 0.3 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence. Approx. 37 kDa band observed in Rat Brain lysates and approx. 35 kDa in Human Liver and Tonsil lysates (calculated MW of 36.1 kDa according to Human NP_002037.2 and 35.8 kDa according to Rat NP_058704.1).](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0008.jpg "Western Blot: GAPDH Antibody [NB300-320] - Staining of Human Liver (A) and Tonsil (B) with antibody at 0.001 ug/mL and Rat Brain lysate (C) with antibody at 0.3 ug/mL (35 ug protein in RIPA buffer). Detected by chemiluminescence. Approx. 37 kDa band observed in Rat Brain lysates and approx. 35 kDa in Human Liver and Tonsil lysates (calculated MW of 36.1 kDa according to Human NP_002037.2 and 35.8 kDa according to Rat NP_058704.1).")
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-320] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of HeLa cells.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-320-img0010.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Staining of paraffin embedded Human Pancreas. Antibody at 2.5 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-320-img0011.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - stai Mutants Have Reduced Levels of alpha-Tubulin, Acetylated alpha-Tubulin, and Kinesin Heavy Chain Protein. Representative western blots of total protein extracted from stai mutant third instar larvae. Heterozygous stai/+ mutant larvae exhibit mild reductions in the levels of alpha-tubulin and acetylated alpha-tubulin compared with wild type larvae. Homozygous stai mutant larvae have dramatic reductions in the levels of alpha-tubulin, acetylated alpha-tubulin and the heavy chain subunit of the microtubule motor protein kinesin compared to wildtype. Df(2L) BSC239 represents a second chromosomal deficiency that excludes the stai gene. GAPDH is used as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0068324), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0005.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Staining of HEK293 (A) and HeLa (B) cell lysate (35 ug protein in RIPA buffer). Antibody at 0.001 ug/mL. Detected by chemiluminescence. Approx 36 kDa band observed in lysates of cell line HEK293 and approx. 35 kDa in HeLa cell lysates.(calculated MW of 36.1 kDa according to Human NP_002037.2).](http://images.novusbio.com/fullsize/GAPDH-Antibody-Western-Blot-NB300-320-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: GAPDH Antibody [NB300-320] - Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing cytoplasmic and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL). Strong expression of the protein seen in the cytoplasm and vesicles of A549 cells.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunocytochemistry-Immunofluorescence-NB300-320-img0009.jpg)
![Immunohistochemistry-Paraffin: GAPDH Antibody [NB300-320] - Upregulation of GAPDH and Tom20 in C6 gliomas. A small glioma labeled with antibodies against GAPDH. The brightness and contrast have been increased. Image collected and cropped by CiteAb from the following publication (//www.biomedcentral.com/1756-0500/8/207), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GAPDH-Antibody-Immunohistochemistry-Paraffin-NB300-320-img0006.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - PAR2 causes contraction of smooth muscle cells from human prostate. (A & B) Decrease in diameter of collagen hydrogels after PAR2 activation with SLIGKV (80 µM). (C) Representative western blot & (D) densitometry showing time dependent increase in level of phosphorylated MLC20 in PSMC after PAR2 is activated. Data represent mean ± SEM of at least three independent experiments. Diameter of collagen hydrogels were measured in ImageJ (version 1.50i) & significance analyzed in Prism (version 7.04) with one‐way ANOVA followed by Tukey's multiple comparison test. *P < 0.05, **P < 0.01 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31198907), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241534329.jpg)
![Immunocytochemistry/ Immunofluorescence: GAPDH Antibody [NB300-320] - Upregulation of GAPDH & Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin & eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (b–d). A small glioma labeled by bisbenzamide (b) & with antibodies against Tom20 (c) & GAPDH (d). The brightness & contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) & along which intensity profiles were measured. f, g Tom20 & GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26032618), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202415392578.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202416205177.jpg)
![Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a−/− mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a−/− mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey’s test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a−/− mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a−/− mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a−/− mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean ± S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey’s test was used for analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-3102024162180.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ_0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241620373.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Down-regulation of hsa_circ_0008896 inhibited proliferation, migration & invasion in vitro. (a) The expression level of hsa_circ_0008896 after si-circ_0008896 transfection was detected using quantitative PCR. (b) CCK8 assay was conducted to measure cell viability after down-regulation of hsa_circ_0008896. (c) The expression levels of two proliferation markers, Ki67 & PCNA after down-regulation of hsa_circ_0008896 were detected using Western blotting. (d) Colony formation assay was conducted to examine proliferation ability after down-regulation of hsa_circ_0008896. (e) The quantification results of (d). (f) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after down-regulation of hsa_circ_0008896. (g) The quantification results of (f). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621234.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - CDC20B was the protein effector regulated by hsa-miR-633. (a) CDC20B level was up-regulated after ox-LDL treatment revealed by Western blotting. (b) CDC20B level was decreased after the treatment of hsa-miR-633 mimics revealed by Western blotting. (c) CDC20B level was increased after the treatment of hsa-miR-633 inhibitor revealed by Western blotting. (d) The luciferase reporter plasmids were constructed as illustrated. (e) Relative luciferase activities after co-transfection CDC20B WT & hsa-miR-633/Control, or CDC20B Mut & hsa-miR-633/Control were measured. (f) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-CDC20B were measured using Western blotting. (g) Colony formation assay was conducted to examine the proliferation abilityafter the treatment of si-CDC20B. (h) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-CDC20B. (i) Quantification results of (g). (j) Quantification results of (h). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-310202416205198.jpg)
![Simple Western: GAPDH Antibody [NB300-320] - MiR-34a affects stroke outcomes via interacting with cytochrome c. (A) WES system image showing CYC, VDAC & GAPDH expression from hemispheres of WT & miR-34a−/− mice at 6 h post-stroke. (B) Relative CYC expression normalized to GAPDH from the data generated by the WES system. CYC level is significantly decreased in ischemic hemispheres of WT mice but no significant changes in miR-34a−/− mice between contralateral hemispheres (Control) & ischemic hemispheres (Ischemia). N = 5 per group, **p < 0.01, One-way ANOVA followed by post hoc Tuckey’s test was used for data analysis. Data are expressed as mean ± S.D. (C) Relative VDAC expression normalized to GAPDH from the data generated by the WES system. VDAC was not significantly altered in WT mice nor miR-34a−/− mice. (D) Multiplexed WES system image showing CYC & GAPDH expression from purified pCECs of WT & miR-34a−/− mice (n = 10 per group, pooled cell samples) at 6 h post-stroke. (E) Relative CYC expression by normalization to GAPDH. A 2.8 fold decrease of CYC level was observed in WT mice but no changes were observed in miR-34a−/− mice between contralateral hemispheres & ischemic hemispheres. (F) A CYC reporter was coexpressed with a miR-34a plasmid, a miR-34a mimic, a miR-34c mimic, or a plasmid control in cultured cerebral vascular endothelial cells for 24 hours. Relative firefly luciferase activity was evaluated & normalized to renilla luciferase activity. Relative firefly luciferase activity was reduced by miR-34a plasmid & miR-34a mimic. The experiment was repeated 3 times & triplicates were used for each analysis. Data represents the mean ± S.D. *p < 0.05. One-way ANOVA followed by post-hoc Tuckey’s test was used for analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32094435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621811.jpg)
![Western Blot: GAPDH Antibody [NB300-320] - Hsa-miR-633 inhibitor could reverse the si-circ_0008896 phenotypes. (a) CCK8 assay was conducted to measure cell viability after up-regulation of hsa-miR-633. (b) The expression levels of two proliferation markers, Ki67 & PCNA after up-regulation of hsa-miR-633 were measured using Western blotting. (c) CCK8 assay was conducted to measure cell viability after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (d) The expression levels of two proliferation markers, Ki67 & PCNA after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor were measured using Western blotting. (e) Colony formation assay was conducted to examine proliferation ability number of colonies after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (f) Quantification results of (e). (g) Transwell migration & invasion assays were conducted to examine the migration & invasion abilities of VSMCs after the treatment of si-circ0008896, hsa-miR-633 inhibitor & si-circ0008896+ hsa-miR-633 inhibitor. (h) Quantification results of (g). *P < 0.05, **P < 0.01, ***P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35212610), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-320_goat-polyclonal-gapdh-antibody-img-3073-31020241621849.jpg)